1![How one patient with a rare disease coped with his genetic disorder How one patient with a rare disease coped with his genetic disorder](https://www.pdfsearch.io/img/d72bb16f5b1c51b6cc104838bc9dc514.jpg) | Add to Reading ListSource URL: www.epp-deutschland.deLanguage: English - Date: 2015-04-23 11:35:57
|
---|
2![LUMIZYME (alglucosidase alfa) for Injection LUMIZYME (alglucosidase alfa) for Injection](https://www.pdfsearch.io/img/eb91eba67f593dc65669ec9321c35a6b.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2010-05-26 09:39:24
|
---|
3![United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP, United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,](https://www.pdfsearch.io/img/c1a89445927722d6410bb86af991ec53.jpg) | Add to Reading ListSource URL: www.patentchallenges.comLanguage: English - Date: 2016-08-09 02:08:12
|
---|
4![Pompe
disease
(Glycogen
storage
disease
type
II) Glycogen
storage
disease
type
II
is
also
known
as
acid
maltase
deficiency
or
generalized
gl Pompe
disease
(Glycogen
storage
disease
type
II) Glycogen
storage
disease
type
II
is
also
known
as
acid
maltase
deficiency
or
generalized
gl](https://www.pdfsearch.io/img/02c3f2d9c6d0bd0bfbd6ac0ad878b3a6.jpg) | Add to Reading ListSource URL: www.finnishlapphund-club.co.ukLanguage: English - Date: 2015-06-20 15:57:04
|
---|
5![May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im](https://www.pdfsearch.io/img/7ba1164d6b62603e3feb67c37e645719.jpg) | Add to Reading ListSource URL: www.apjohnventures.comLanguage: English - Date: 2014-05-29 15:30:33
|
---|
6![Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final](https://www.pdfsearch.io/img/f50e1a77dccef4f91a3562c2aaea87b7.jpg) | Add to Reading ListSource URL: www.apjohnventures.comLanguage: English |
---|
7![Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi](https://www.pdfsearch.io/img/a57b62187398d430c2266b3ecdaa12da.jpg) | Add to Reading ListSource URL: www.alexion-synagevatransaction.comLanguage: English - Date: 2015-05-06 06:45:36
|
---|
8![](https://www.pdfsearch.io/img/cf5feeaeeb73db882b648ca10c21e266.jpg) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2014-10-01 21:56:22
|
---|
9![](https://www.pdfsearch.io/img/a6ae29cae6ab5618ee52f9c52f104ddb.jpg) | Add to Reading ListSource URL: www.hrsa.govLanguage: English |
---|
10![Microsoft WordAlglucosidase Genzyme PSD March 2013 FINAL.doc Microsoft WordAlglucosidase Genzyme PSD March 2013 FINAL.doc](https://www.pdfsearch.io/img/81faa2c0b2d47610a74d82e9eba9ce59.jpg) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2014-10-01 21:56:23
|
---|